Advertisement

Topics

Search Results for "Crizotinib Src Kinase"

09:40 EDT 1st May 2016 | BioPortfolio

Matching Channels

Polo like kinase Plk 1

Polo-like kinase (Plk) is an important cell cycle regulatory kinase that has been implicated in a multitude of cell cycle events. Plks form a family of four different proteins that regulates many as...

MAP kinase kinase MEK Inhibitors

The mitogen activated protein kinases (MAPKs) are conserved proteins that regulate cell growth, division and death.  The MAPK pathway has emerged as the crucial route between membrane-bound Ras...

Bcr Abl and Src Kinase Inhibitors

Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia (Ph) chromosome, which results from a reciprocal translocation between the long arms of the chromosomes 9 and 22 t...

Checkpoint kinase 1 CHK 1

Progression through the cell cycle is monitored by surveillance mechanisms known as cell cycle checkpoints. Dysfunction in cell cycle checkpoints leads to genomic instability and contributes to tumo...

Kinases Raf Inhibitors

The Ras-Raf-MEK-ERK (ERK) pathway is a logical therapeutic target because it represents a common downstream pathway for several key growth factor tyrosine kinase receptors which are often mutated or...

Matching News

A novel mechanism of crizotinib resistance in a ROS1+ NSCLC patient

Molecular analysis of a tumor biopsy from a proto-oncogene 1 receptor tyrosine kinase positive (ROS1+) patient with acquired crizotinib resistance revealed a novel mutation in the v-kit Hardy Zuckerma...

Novel mechanism of crizotinib resistance in a ROS1+ NSCLC patient

Molecular analysis of a tumor biopsy from a proto-oncogene 1 receptor tyrosine kinase positive (ROS1+) patient with acquired crizotinib resistance revealed a novel mutation in the v-kit Hardy Zuckerma...

Bronchial carcinoma: Added benefit of crizotinib for first-line treatment not proven

The drug crizotinib (trade name: Xalkori) has been available since 2012 for patients with advanced non-small cell lung cancer (bronchial carcinoma) who have a high activity of the enzyme anaplastic ly...

Pfizer lung cancer treatment gets expanded EU approval

Pfizer UK has received European Commission approval for a label update to expand use of Xalkori (crizotinib) to first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced n...

FDA Approves New Oral Therapy for ALK-Positive Lung Cancer

The FDA has approved alectinib (Alecensa, Genentech) to treat patients with advanced (metastatic) anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) whose disease has worsene...

Resensitization to Crizotinib in ALK-Mutated Lung Cancer: A Case Study (FREE)

When the patient relapsed after treatment with lorlatinib, a new mutation enhanced binding to crizotinib.

Intracranial Efficacy of Crizotinib for Patients with ALK-Positive Lung Cancer (FREE)

Intracranial disease control was better with crizotinib than with chemotherapy.

FDA Approves crizotinib capsules for metastatic non-small cell lung cancer

On March 11, 2016, the US Food and Drug Administration approved crizotinib capsules (Xalkori, Pfizer, Inc.) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumou...

Matching PubMed Articles

Complete and Repeated Response of a Metastatic ALK-rearranged Inflammatory Myofibroblastic Tumor to Crizotinib in a Teenage Girl.

Inflammatory myofibroblastic tumors (IMT) are rare tumors in children and young adults, considered by the World Health Organization to be intermediate malignancies and rarely metastasizing, with the p...

Crizotinib-Induced Abnormal Signal Processing in the Retina.

Molecular target therapy for cancer is characterized by unique adverse effects that are not usually observed with cytotoxic chemotherapy. For example, the anaplastic lymphoma kinase (ALK)-tyrosine kin...

Crizotinib Associated with Ground-Glass Opacity Predominant Pattern Interstitial Lung Disease: A Retrospective Observational Cohort Study with a Systematic Literature Review.

Crizotinib, an oral tyrosine kinase inhibitor that targets anaplastic lymphoma kinase, has proven to offer sustained progression-free survival in anaplastic lymphoma kinase-rearranged non-small-cell l...

A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme.

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor. Despite the advances in surgery, radiotherapy and chemotherapy, patient survival averages only 14.6 months. In most...

Crizotinib versus platinum-based double-agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase-positive lung adenocarcinoma.

To explore the efficacy and safety of crizotinib versus platinum-based double agent chemotherapy as the first-line treatment in patients with advanced anaplastic lymphoma kinase (ALK)-positive lung ad...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement